Q-omics provides the consensus-scored LNX1-AS2 profile across patient tissues and cancer cell-line models. LNX1-AS2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LNX1-AS2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, LNX1-AS2 RNA expression shows 14,937 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KIRC, and THYM as cancer lineages where LNX1-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LNX1-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LNX1-AS2 survival associations across molecular data types. LNX1-AS2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LNX1-AS2 RNA expression–survival associations across cancer types. High LNX1-AS2 expression shows unfavorable associations in CESC, LGG, LUAD and KIRP, but favorable associations in ACC and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for LNX1-AS2 RNA expression.
This table summarizes LNX1-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LNX1-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LNX1-AS2 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LUAD, COAD, LUSC and PAAD. The KIRC box plot shows higher LNX1-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.694, t-test p < 0.001).
This table shows molecular features associated with LNX1-AS2 in patient tissues and cancer cell lines. In patient samples, LNX1-AS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
